JP2024521418A5 - - Google Patents

Info

Publication number
JP2024521418A5
JP2024521418A5 JP2023575836A JP2023575836A JP2024521418A5 JP 2024521418 A5 JP2024521418 A5 JP 2024521418A5 JP 2023575836 A JP2023575836 A JP 2023575836A JP 2023575836 A JP2023575836 A JP 2023575836A JP 2024521418 A5 JP2024521418 A5 JP 2024521418A5
Authority
JP
Japan
Prior art keywords
patient
inhibitor
antigen
cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033058 external-priority patent/WO2022261467A1/en
Publication of JP2024521418A publication Critical patent/JP2024521418A/ja
Publication of JP2024521418A5 publication Critical patent/JP2024521418A5/ja
Pending legal-status Critical Current

Links

JP2023575836A 2021-06-11 2022-06-10 放射性免疫複合体とチェックポイント阻害剤併用療法 Pending JP2024521418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209736P 2021-06-11 2021-06-11
US63/209,736 2021-06-11
PCT/US2022/033058 WO2022261467A1 (en) 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2024521418A JP2024521418A (ja) 2024-05-31
JP2024521418A5 true JP2024521418A5 (cg-RX-API-DMAC7.html) 2025-06-05

Family

ID=84426354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575836A Pending JP2024521418A (ja) 2021-06-11 2022-06-10 放射性免疫複合体とチェックポイント阻害剤併用療法

Country Status (13)

Country Link
US (1) US20240285818A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351662A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521418A (cg-RX-API-DMAC7.html)
KR (1) KR20240021227A (cg-RX-API-DMAC7.html)
CN (1) CN117794585A (cg-RX-API-DMAC7.html)
AR (1) AR126128A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022291150A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222948A1 (cg-RX-API-DMAC7.html)
IL (1) IL309243A (cg-RX-API-DMAC7.html)
MX (1) MX2023014778A (cg-RX-API-DMAC7.html)
TW (1) TW202317204A (cg-RX-API-DMAC7.html)
WO (1) WO2022261467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3265502A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DOTA ANTIBODY CONJUGATES VHH
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Similar Documents

Publication Publication Date Title
JP2022513700A5 (cg-RX-API-DMAC7.html)
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
JP6223962B2 (ja) トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット
JP5992435B2 (ja) 循環からの生体分子の除去剤
EP3648801B1 (en) Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
JP7194595B2 (ja) グランザイムbを指向するイメージングおよび治療
JP2020518674A5 (cg-RX-API-DMAC7.html)
JP2020519643A (ja) Msln標的三重特異性タンパク質及びその使用方法
JP2014500307A5 (cg-RX-API-DMAC7.html)
JP2006526408A (ja) 多価タンパク質複合体
RU2019139432A (ru) Фармакокинетическая оптимизация бифункциональных хелатов и их применение
JP2022511471A5 (cg-RX-API-DMAC7.html)
JP7836270B2 (ja) 抗dota/抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのdota-ハプテン組成物
JP2020518673A5 (cg-RX-API-DMAC7.html)
US20210171651A1 (en) Bispecific antibody compositions and related methods for improved pretargeted radioimmunotherapies
JP2000510119A (ja) ガンに対する標的コンビネーション免疫療法
TW202128732A (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
EP3890790A1 (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
EP3765523A1 (en) Bispecific binding agents and uses thereof
TW201627286A (zh) 放射性醫藥複合物
EP4408839A1 (en) Macrocycle containing compounds and radiolabelled complexes thereof, as ligands in targeted radiotherapy applications
US12508329B2 (en) Radiotherapeutic and companion imaging agents to target MC1R
KR20080099279A (ko) 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트
JP2018168068A (ja) 抗ポドプラニン抗体及び抗体薬物複合体
CN1905900A (zh) Erb抗原的靶向作用